| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/16/2003 | WO2002032916A3 Sixteen-membered macrolide compounds |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002022171A3 Pharmaceutical composition having specific water activity |
| 01/16/2003 | WO2002022107A3 Pharmaceutical composition having modified carrier |
| 01/16/2003 | WO2002022080A8 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001093913A3 T cell receptor fusions and conjugates and methods of use thereof |
| 01/16/2003 | WO2001092490A3 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001074898A3 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 01/16/2003 | WO2001060315A3 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 01/16/2003 | WO1995032984A8 New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs |
| 01/16/2003 | US20030013890 Such as 2-(1-chloro-cycloprop-1-yl)-1-(2-chloro-phenyl)-3-(4,5-dihydro-1,2,4 -triazole-5-thiono-1-yl)-propan-2-ol; microbiocides; fungicides |
| 01/16/2003 | US20030013860 Azalide isomers, water, and acids |
| 01/16/2003 | US20030013850 Antiinflammatory agents |
| 01/16/2003 | US20030013844 Multimerization of HIV-1 Vif protein as a therapeutic target |
| 01/16/2003 | US20030013770 Aminobenzophenones as inhibitors of il 1b and tnf |
| 01/16/2003 | US20030013755 Autoinducer compounds |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013751 Viricides; enzyme inhibitors |
| 01/16/2003 | US20030013739 Synergistic mixtures; side effect reduction |
| 01/16/2003 | US20030013737 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 01/16/2003 | US20030013724 Novel prolines as antimicrobial agents |
| 01/16/2003 | US20030013721 Antiinflammatory agents; immunology; cardiovascular disorders; rheumatic disorders |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013697 Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal |
| 01/16/2003 | US20030013680 Oral administering of mucopolysaccharides |
| 01/16/2003 | US20030013665 Novel macrolide antibiotics |
| 01/16/2003 | US20030013663 Therapy for bacteria infections that are drug resistant |
| 01/16/2003 | US20030013659 Herpes virus |
| 01/16/2003 | US20030013190 Altered strain of the modified vaccinia virus ankara (mva) |
| 01/16/2003 | US20030013122 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/16/2003 | US20030013095 Nuclcic acid enzyme for use in the prevention and treatment of infections and cancer |
| 01/16/2003 | US20030013081 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 01/16/2003 | US20030013077 Binding to monoclonal antibodies; detection of Kaposi's sarcoma |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012749 Applying a preparation comprising water, urea and a film-forming agent to remove and treat diseased nails affected by onychomycosis |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | US20030010715 Use of cationic exchange chromatography on solid matrix carried out at basic pH |
| 01/16/2003 | CA2785699A1 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | CA2453173A1 Mycobacterial antigens expressed during latency |
| 01/16/2003 | CA2453100A1 Novel human hepatoma lines, methods for obtaining same and uses thereof |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2453062A1 Group b streptococcus bvh-a5 antigens and corresponding dna fragments |
| 01/16/2003 | CA2452686A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | CA2452666A1 Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2452592A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | CA2452580A1 Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
| 01/16/2003 | CA2452372A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2452119A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451391A1 C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| 01/15/2003 | EP1275720A2 Histidyl-trna synthetase of staphylococcus aureus |
| 01/15/2003 | EP1275716A2 Modified DNA molecule, recombinant containing the same thing, and uses thereof |
| 01/15/2003 | EP1275713A1 Tlr/cd14 binding inhibitor |
| 01/15/2003 | EP1275388A1 Tnf- alpha inhibitors |
| 01/15/2003 | EP1274853A1 Materials and methods relating to immune responses to fusion proteins |
| 01/15/2003 | EP1274852A2 Targeted vaccine delivery systems |
| 01/15/2003 | EP1274851A1 A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274842A2 Lipid binding protein 4 |
| 01/15/2003 | EP1274841A2 Regulation of human cyslt2-like gpcr protein |
| 01/15/2003 | EP1274840A2 Ligand for herpes simplex virus entry mediator and methods of use |
| 01/15/2003 | EP1274732A1 Secretory tyrosine phosphatases from mycobacteria |
| 01/15/2003 | EP1274724A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274713A1 Anti-viral pyrimidine nucleoside analogues |
| 01/15/2003 | EP1274705A1 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| 01/15/2003 | EP1274704A1 Process for preparing 5'-acetylstavudine |
| 01/15/2003 | EP1274701A1 Chemical compounds |
| 01/15/2003 | EP1274694A1 Novel compounds |
| 01/15/2003 | EP1274683A2 Heterocyclic acylsulfimides, a method for their production, agents containing the same and their use as pesticides |
| 01/15/2003 | EP1274682A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 01/15/2003 | EP1274453A2 Recombinant intracellular pathogen vaccines and methods for use |
| 01/15/2003 | EP1274450A2 Cytokine uses; compositions; methods |
| 01/15/2003 | EP1274445A2 Use of steroidal alkaloids to reverse multidrug resistance |
| 01/15/2003 | EP1274443A1 Micelles |
| 01/15/2003 | EP1274441A1 Respiratory compositions |
| 01/15/2003 | EP1274440A1 Medical combinations comprising tiotropium and mometasone |
| 01/15/2003 | EP1274439A1 Medical combination comprising salmeterol and budesonide |
| 01/15/2003 | EP1274436A1 Medical compositions comprising (r,r)-formoterol und rofleponide |
| 01/15/2003 | EP1274434A1 Medical combinations comprising tiotropium and rofleponide |
| 01/15/2003 | EP1274432A1 Compositions containing itraconazole with improved bioavailability and narrow intra- and inter-individual variation of its absorption |
| 01/15/2003 | EP1274428A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274421A2 Use of substances that act as cascade inhibitors of the raf/mek/erk signal cascade, for producing a medicament to treat dna and rna viruses |
| 01/15/2003 | EP1274420A1 Microbial inhibitory compositions |
| 01/15/2003 | EP1274415A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274413A2 Il-8 receptor antagonists |
| 01/15/2003 | EP1274407A2 Uses of ppar-gamma agonists in neutrophil-induced diseases |
| 01/15/2003 | EP1274398A2 Effervescent granules and methods for their preparation |
| 01/15/2003 | EP1274397A2 Drug delivery composition and device |
| 01/15/2003 | EP1274305A2 Aids ancestral viruses and vaccines |
| 01/15/2003 | EP1155017B1 [1,8] naphthyridine derivatives having antiviral activity |